> Back to EJC

Recent editions

  • June 2014
    Hans Clevers on important research into stem cells in normal gut tissue.
  • May 2014
    Carolyn Taylor and Paul McGale find evidence to clarify guidelines for radiotherapy after mastectomy.
  • April 2014
    Richard Sullivan and Ajay Aggarwal on how physicians can tackle the issue of affordability in cancer care.
  • March 2014
    The 1st EORTC Cancer Survivorship Summit addressed the practical problems faced by cancer patients.
  • February 2014
    Charles Swanton on a study that maps genetic changes in cancers over time.
  • January 2014
    Presidents of various cancer societies make predictions for the coming year.
  • December 2013
    Precision diagnostics have great potential, but changes are needed to make them more available.
  • November 2013
    Highlights of the European Cancer Congress - cancer society presidents give their view.
  • October 2013
    Richard Schilsky on the changes needed as personalised medicine enters the clinic.
  • September 2013
    A new advance in immunotherapy is discussed by Jean-Charles Soria and Caroline Robert.
  • July/August 2013
    EORTC President Roger Stupp on challenges for clinical trials research.

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

 

EJC News Focus – October 2013

Loading EJC News Focus video

'New ways of learning are needed' as personalised medicine enters routine practice

Prospective observational registries, which record every clinical encounter with every patient, are going to be the way to continue progress in our understanding of cancer, according to Richard L Schilsky, Chief Medical Officer of the American Society of Clinical Oncology (ASCO).

Genetic characterisation has led to cancers which were traditionally considered common becoming instead a collection of rare diseases. It means that there are now too many cancers, too many drugs in development and not enough patients, time or money to study everything by doing clinical trials, he says.

In this month's EJC News Focus, Schilsky tells Helen Saul that as personalised medicine enters the clinic, changes are needed – and are happening – in research, development and the regulation of new cancer drugs.